Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardio-Renal panel to address Revatio, phosphate binders

Executive Summary

FDA's Cardiovascular and Renal Drugs Advisory Committee will meet Oct. 16 to discuss extending the use of phosphate binders to the pre-dialysis population. Shire, Genzyme and Fresenius - all of whom have phosphate binders approved for use in controlling serum phosphorus levels in dialysis patients - are scheduled to speak at the first day of the meeting. Genzyme has an NDA pending for Renagel (sevelamer) follow-on Renvela for the pre-dialysis indication. Fresenius markets PhosLo (calcium acetate) and Shire markets Fosrenol (lanthanum) in the United States. The panel will also discuss data requirements and study designs for a pediatric indication for Pfizer's Revatio (sildenafil) in pulmonary arterial hypertension Oct. 17...

You may also be interested in...

Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”

Colfax Plans To Split To Form Separate Medtech And Fabtech Companies

The yet-to-be-named medtech company will focus on orthopedic implants and bracing and recovery devices.

What Does A Typical Refuse-To-File Letter Look Like?

Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts